Literature DB >> 29715576

Prognostic factors and the management of anaplastic meningioma.

Gui-Jun Zhang1, Yun-Sheng Zhang2, Guo-Bin Zhang1, Da Li1, Li-Wei Zhang1, Zhen Wu1, Jun-Ting Zhang3.   

Abstract

OBJECTIVES: Anaplastic meningiomas (AMs)tend to have a higher local recurrence rate and metastasize. but few studies have reported on the prognosis and management of patients with AM, this study aimed to increase the understanding of the prognosis, management and history of AM. PATIENTS AND METHODS: All patients (n = 56) underwent surgeries in our hospital between December 2008 and January 2016. Postoperative pathology reports confirmed the diagnosis of AM. Prognostic factors and the management were analysed in this study. AM was then divided into two groups. One group was primary AM, the other group was secondary AM.
RESULTS: Of all the 56 AM patients, 31 were male and 25 were female (male to female ratio of 1.24:1). The 1-, 3-, and 5-year progression-free survival (PFS) rates were 78.6%, 41.1% and 29.7%, respectively, and the corresponding overall survival (OS) rates were 82.1%, 50.1% and 45.0%, respectively. Homogeneous contrast might be a potential better prognostic factor for PFS (HR = 1.824, P = 0.083). Treatment with postoperative radiotherapy (PRT) was significantly associated with longer PFS (HR = 0.390, P = 0.007) and OS (HR = 0.376, P = 0.008) according to univariate analysis. Gross-total resection (GTR) was a favourable factor for PFS (HR = 2.059, P = 0.035) and OS (HR = 2.802, P = 0.004).
CONCLUSION: Achieving GTR is a favourable treatment strategy for patients with AM in our study and patients receiving PRT after resection is essential.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anaplastic meningioma; Prognosis; Treatment; Tumor progression

Mesh:

Year:  2018        PMID: 29715576     DOI: 10.1016/j.clineuro.2018.03.028

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  4 in total

1.  Clinical and histopathological predictors of outcome in malignant meningioma.

Authors:  Andrea D Maier; Jiri Bartek; Frank Eriksson; Heidi Ugleholdt; Marianne Juhler; Helle Broholm; Tiit I Mathiesen
Journal:  Neurosurg Rev       Date:  2019-03-13       Impact factor: 3.042

2.  Prognostic Factors and Treatment Strategies for Elderly Patients with Malignant Meningioma: A SEER Population-Based Study.

Authors:  Songshan Feng; Jing Li; Fan Fan; Zeyu Wang; Qian Zhang; Hao Zhang; Ziyu Dai; Xun Zhang; Peng Luo; Zaoqu Liu; Jian Zhang; Zhuoyi Liu; Quan Cheng
Journal:  Front Oncol       Date:  2022-05-13       Impact factor: 5.738

3.  Analysis of Prognostic Factors of World Health Organization Grade Ⅲ Meningiomas.

Authors:  Weidong Tian; Jingdian Liu; Kai Zhao; Junwen Wang; Wei Jiang; Kai Shu; Ting Lei
Journal:  Front Oncol       Date:  2020-12-07       Impact factor: 6.244

Review 4.  Diagnostic and Therapeutic Strategy in Anaplastic (Malignant) Meningioma, CNS WHO Grade 3.

Authors:  Vincenzo Di Nunno; Caterina Giannini; Sofia Asioli; Alfredo Conti; Julia Furtner; Damiano Balestrini; Alicia Tosoni
Journal:  Cancers (Basel)       Date:  2022-09-26       Impact factor: 6.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.